Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.

Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017 Feb;31(1):31-44 Authors: Chuang JC, Liang Y, Wakelee HA Abstract The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non-small cell lung cancer. Neoadjuvant chemotherapy lacks the same level of data as adjuvant treatment, but meta-analyses of this approach support its use. Selection of patients who are most likely to benefit from chemotherapy remain elusive. Ongoing adjuvant trials are exploring biomarkers, molecularly targeted agents, postoperative radiation therapy, and immunotherapy. PMID: 27912832 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/27912832?dopt=Abstract

Source: Clinical Lung Cancer - December 5, 2016 Category: Cancer & Oncology Authors: Chuang JC, Liang Y, Wakelee HA Tags: Hematol Oncol Clin North Am Source Type: research